Loading clinical trials...
Loading clinical trials...
A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone With Background Dapagliflozin in Subjects With Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)
Conditions
Interventions
Apabetalone
Locations
3
Jordan
The Speciality Hospital
Amman, Jordan
MNGHA- King Abdulaziz Hospital
Al Mubarraz, Saudi Arabia
Al Kuwait Hospital
Dubai, Dubai, United Arab Emirates
Start Date
April 15, 2025
Primary Completion Date
December 30, 2025
Completion Date
March 30, 2026
Last Updated
April 18, 2025
NCT07189936
NCT05421208
NCT05926505
NCT06456502
NCT06086379
NCT07074158
Lead Sponsor
Resverlogix Corp
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions